There are currently 69 active clinical trials seeking participants for Esophageal Cancer research studies. The states with the highest number of trials for Esophageal Cancer participants are Ohio, Illinois, California and Michigan.
Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Recruiting
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927), Tucson, Arizona +36 locations
Conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Recruiting
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancerovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: City of Hope, Duarte, California +60 locations
Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
Brodalumab in the Treatment of Immune-Related Adverse Events
Recruiting
The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Retrospective Review of Esophageal Cancer at MSKCC
Recruiting
Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/07/2025
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Esophageal Cancer, Esophagus Cancer
Exercise Prehabilitation for Locoregional Esophageal Cancer
Recruiting
The purpose of the study is to examine the feasibility and acceptability of exercise "prehabilitation" for patients preparing for esophageal cancer resection (removal).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Esophageal Cancer
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Recruiting
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +17 locations
Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Esophageal Cancer Multimodal Prehabilitation Study
Recruiting
The goal of this research study is to investigate the feasibility of implementing a prehabilitation program that aims to improve a patient's physical, nutritional, and sleep health before surgery in an older, at-risk group with esophageal cancer.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Esophageal Cancer, Esophageal Neoplasms
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Recruiting
This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder, liver, neuroendocrine tumor of gastrointestinal origin). This study has 3 components as follows- 1. Ensuring appropriate biomarker testing and evidence-based care: Biomarkers are molecules in the tumor or blood that indicate normal or abnormal processes in participant's bod... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Gastrointestinal Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Esophageal Cancer, Stomach Cancer, Appendix Cancer, Pancreas Cancer, Liver Cancer, Neuroendocrine Tumors
Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy
Recruiting
This is a Phase I trial evaluating the safety of personalized radiation therapy based on levels of hypoxia identified on FMISO-PET and MRI. All patients will receive a baseline FMISO positron emission tomography (PET) and MRI to identify levels of hypoxia. Patients with tumor hypoxia will receive a higher dose of radiation therapy. Subjects who do not have hypoxic tumors will be treated with the standard-of-care radiation regimen. After fraction 10 of radiation therapy, an additional MRI will be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Esophageal Cancer
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Recruiting
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of MK-2870 plus paclitaxel versus Ramucirumab plus paclitaxel, for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927), Tucson, Arizona +36 locations
Conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Recruiting
This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with advanced, recurrent or metastatic solid tumors with a SMARCA4 mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Florida Cancer Specialists, West Palm Beach, Florida +5 locations
Conditions: Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Recruiting
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Sarah Cannon Research Institute, Denver, Colorado +4 locations
Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer